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Case presentation
A 47-year-old man, an executive at a financial institution, entered the
hospital for the evaluation of recurrent nephrolithiasis and the sponta-
neous passage of a renal stone 3 months previously. The patient had
been in good health except for a 15-year history of recurrent renal
stones. The stones, which had occurred bilaterally, had been passed at
a rate of 5 per year for the last 5 years; in the first 10 years he had passed
a total of 5 stones. The patient had undergone cystoscopy with stone
extraction on three occasions and recently had been treated with
extracorporeal shock-wave lithotripsy for a partially obstructing stone
in the left proximal ureter. Crystallographic analysis of these stones had
revealed that all were composed of 100% calcium oxalate mono- and
dihydrate. Radiography disclosed continuing stone formation by docu-
menting the presence of new stones during the preceding 8 months.
The patient had no history of gastrointestinal disease, excessive sun
exposure, or current drug usage, including antacids and vitamin sup-
plements. He had never received neck irradiation, nor had he experi-
enced a urinary tract infection, His father and paternal uncle both had
passed kidney stones of unknown type. The patient had undergone
multiple evaluations for the cause of his stone diathesis but always had
been told that "all studies were normal." He was specifically told that
hypercalcemia had never been detected.
Review of his diet by a dietician showed that he usually consumed
110 g of protein/day, with an 80 g intake of animal protein. His calcium
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intake was estimated to be 900 mg/day. He stated that he consumed
"large amounts" of fluid.
Physical examination revealed a moderately obese individual, with a
blood pressure of 1 24/86 mm Hg; pulse, 80 beats/mm; and respirations,
16/mm. The rest of the examination was normal.
Laboratory studies revealed fasting serum levels as follows: sodium,
142 mEq!liter; potassium, 3.8 mEq/liter; chloride, 105 mEq/liter; carbon
dioxide, 28 mEq/liter; BUN, 14 mg/dl; creatinine, 1.0 mg/dl; glucose,
126 mg/dl; calcium, 9.6 mg/dl; phosphate, 2.6 mg/dl; uric acid, 4.6
mg!dl; and albumin, 4.1 g/dl.
Urinalysis revealed a pH of 5.2; specific gravity, 1.018; negative
dipstick; 1—3 red blood cells/high-power field, 0—2 white blood cells!
high-power field, no casts, no bacteria, and occasional calcium oxalate
crystals. Without dietary manipulation, 24-hour urine excretions were:
sodium, 298 mEq; calcium, 367 mg; oxalatc, 36mg; citrate, 487 mg; uric
acid, 864 mg; phosphate, 1056 mg; urea nitrogen, 13 g; creatinine, 1.4 g;
and volume, I liter.
The patient's diet was modified as follows. Protein intake was
restricted to 65 g/day, and sodium intake to 125 mEg/day; he was
instructed to avoid oxalate-rich foods. It was recommended that he
drink two 12 oz. glasses of water every 2 hours while awake.
Urine studies after 6 weeks of the modified diet revealed the following
24-hour excretions: calcium, 221 mg; sodium, 135 mEq; oxalate, 22 mg;
citrate, 687 mg; uric acid, 566 mg; urea nitrogen, 8 g; creatinine, 1.2 g;
and volume, 2.6 liters.
During a 3-year followup, the patient consistently has maintained
similar excretion rates and has neither developed nor passed a stone.
Discussion
Da. STANLEY GOLDFARB (Attending Physician, Hospital of
the University of Pennsylvania, and Associate Professor of
Medicine, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania): This man presents with the typical
clinical history and the usual pathophysiologic abnormalities
seen in patients with recurrent calcium-oxalate nephrolithiasis.
This patient had recurrent stone disease and had high excre-
tions of calcium, uric acid, and sodium as well as decreased
excretion of citrate while ingesting a diet high in protein,
purines, and sodium. Since being evaluated at a "stone cen-
ter," that is, a specialized treatment center, and treated with a
diet lower in protein, purines, and sodium, along with a high
fluid intake, he has not passed a stone for 3 years.
The impact of diet on the formation of kidney stones has been
recognized for many years [1, 21, yet pharmacologic therapy
continues to be relied on unduly for the prevention of stone
formation. In fact, the evidence that drug treatment (principally
thiazide diuretics) prevents recurrent nephrolithiasis is quite
weak 3J and the long-term safety of such drugs has been
questioned [4]. Indeed, pharmacologic therapies are preferred
by many despite increasing evidence of marked benefit of
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Fig. 1. Percentage of patients free of stone recurrence at 5 years (the
"stone clinic effect"). All refers to the entire population studied,
hypercalciuric refers to those patients hypercalciuric (>300 mg/24hours
in men, >250 mg/24 hours in women), and hyperuricosuric to those
patients hyperuricosuric (>800 mg/24 hours in men, >750 mg/24 hours
in women) on entry into the study. Patients received dietary advice
(increase fluid intake to >2500 nil/24 hours, restrict dairy products and
meat intake). (Data are from Ref. 5.)
simple dietary and fluid modification at a clinic specializing in
recurrent nephrolithiasis (Fig. 1) [5].
Nephrolithiasis is a common clinical disorder. Estimates of
its prevalence range from 1% to as high as 15% in the general
population [6]. Although recorded evidence exists for kidney
stones in virtually all civilizations, an enormous and increasing
occurrence of stones in the upper urinary tract has character-
ized the twentieth century, particularly in the temperate regions
of the economically developed world [7].
The epidemic of upper-urinary-tract stones that has swept the
developed nations of the world closely correlates with eco-
nomic affluence and with an increased per-capita expenditure
on food [8]. These observations suggest that therapy aimed at
reducing or eliminating the lithogenic components of the diet
could effectively and safely prevent recurrent stone disease in
individuals at risk. In this review I will examine the hypothesis
that dietary factors are responsible for many cases of urolithi-
asis and that in many patients, dietary therapy is the optimal
form of prevention.
Role of dietary protein
Anderson first showed the strong correlation between eco-
nomic affluence and upper-urinary-tract stones [2]. The concept
that the high incidence of bladder stones in southern Asia and
the Indian subcontinent was related to protein malnutrition had
been well accepted by the early l960s [9]. In fact, a specific
dietary protein supplement in Sicily following World War II
decreased the incidence of hospital admissions for bladder
stones 60-fold [21. Because upper-urinary-tract stones and not
bladder stones were commonly seen in the more affluent
societies, Anderson proposed that the risk of upper tract
disease also was a function of diet, but that in this case,
relatively high dietary protein intake correlated with upper-
tract nephrolithiasis [2]. The relationships among affluence,
diet, and stones were particularly impressive and could be
demonstrated across heterogeneous societies and within a
single country. In northern and western regions of India, for
example, animal protein intake is approximately 100% greater
than in the southern and eastern regions; the risk of upper-tract
Fig. 2. Comparison of the annual number of hospital discharges (upper
panel) and the consumption of animal protein (lower panel) in the United
Kingdom between 1960 and 1980 [101.
stone formation, measured by hospitalization rates, was
23.6/1000 admissions in the north and west compared with only
5./l000 admissions in the south and east [2]. Robertson and
coworkers subsequently established a similar correlation be-
tween the frequency of upper-tract stone disease (estimated by
the frequency of hospital discharges for a kidney stone) and the
per-capita expenditure on food in different geographic regions
of the United Kingdom [10, 11]. The relationship was strongest
for the amount of animal protein consumed (Fig. 2). Similar
data have been gathered in a number of countries, including
Germany [12] and Austria [13].
During the twentieth century, the incidence of clinical stone
disease in Great Britain [14], Germany [12], Italy [7], and
Norway [2], as determined by hospital admissions or by au-
topsy analysis, was closely correlated with the political and
economic circumstances in each society. During World Wars I
and II, as animal protein consumption fell, the incidence of
stone disease declined (Fig. 3).
These observations, although consistent with the hypothesis
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Fig. 3. Frequency of urolithiasis in postmortem material in Leipzig during
the 20th century [12]. Ordinate shows the percentage of postmortem
examinations in which a urinary stone was found. Abscissa shows the
year, the number of postmortem examinations (PM), and the number of
stones.
that dietary protein is a crucial factor, suggest a number of other
links betweea diet and stone formation. Other variables that
parallel the intake of dietary protein could be the real causes of
stone formation. Proof that the quantity of animal protein eaten
is important in the causation of nephrolithiasis depends on
evidence that would directly link the dietary intake of animal
protein with increased stone formation. For example, correla-
tion should exist between protein intake and the urinary find-
ings associated with increased rates of stone formation, such as
hypercalciuria and hypocitraturia. Moreover, proving that di-
etary protein plays an important role in individual patients
requires establishing with reasonable certainty the following
three points. First, dietary protein intake should be increased in
patients with recurrent nephrollthiasis compared with controls.
Second, restriction of dietary protein intake should decrease
the rate of stone formation in a carefully designed study. Third,
the mechanism(s) for the lithogenic action of dietary protein
should be defined.
Such proof does not yet exist, but each point can be partially
addressed. Robertson and colleagues have shown a correlation
between the rise of stone disease and per-capita food expendi-
ture [10, 11]; they also found that dietary animal protein and
total protein intake were increased in a group of patients with
recurrent nephrolithiasis compared with controls [15]. Their
populations were not well matched, however, for level of
economic well-being. Because kidney stones, for whatever
reason, are more common in patients who belong to more
affluent social classes, the variable of economic status must be
controlled. When such matching was carried out in other
studies, the intake of all dietary constituents studied did not
differ in recurrent stone formers and in controls [16].
In a large study that my colleagues and I performed at the
Stone Evaluation Center of the University of Pennsylvania, we
also found that patients with recurrent calcium nephrolithiasis
consumed a diet that was similar in composition to that of case
controls [17]. We discerned a clear linear relationship, howev-
er, between dietary protein intake, estimated by urinary urea
nitrogen excretion, and urinary calcium excretion. More impor-
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Fig. 4. Urine calcium excretion (mg/24 hours) and urinary urea nitrogen
excretion (g/24 hours), an index of dietary protein ingestion, are plotted for
male (upper panel) and female subjects in a large (155 cases, 200 worksite
controls, 134 clinic controls) epidemiologic study of risk factors for
calcium nephrolithiasis. Linear slope was significantly different for male
and female cohorts, but the addition of a quadratic term significantly
improved the analysis for the female subjects. The differing slopes of cases
and controls imply increased sensitivity to the hypercalciuric action of
increased dietary protein intake in stone formers [171.
tant, the slope of this relationship was much greater for the
patients with recurrent nephrolithiasis than for the controls.
This finding suggests to us that the degree of calciuria and the
risk of stone formation in patients with recurrent nephrolithiasis
depends on dietary protein intake. We speculated that patients
with recurrent nephrolithiasis are more sensitive to the calciuric
action of protein because any increment in dietary protein
intake elicited a proportionately greater increase in calciuria in
the stone patients than in controls (Fig. 4).
The hypothesis that patients with recurrent nephrolithiasis
are particularly sensitive to dietary intake, that is, that they
have greater calciuria for any increment in dietary protein,
helps explain why populations show differences based on level
of affluence, whereas individuals within a given economic class
need not differ in diet but still differ in stone risk. At very high
levels of dietary protein, a greater proportion of the population
will be at risk of altered urinary composition that favors stone
formation. Within a group of individuals at a given dietary
protein intake, some will be particularly susceptible to stone
formation. Such increased sensitivity in a subpopulation of
individuals also can occur following ingestion of other dietary
constituents thought to increase the risk of stone disease, such
as carbohydrate [18], sodium [19], and oxalate [20].
A second form of evidence that dietary protein contributes to
the pathogenesis of nephrolithiasis is the observation that the
risk of nephrolithiasis is markedly reduced in people, such as
vegetarians, who eat little or no protein. In studies in Great
Britain, the prevalence of stone formation was threefold less in
vegetarians than in the general population [21]. In fact, the
prevalence of stone formation in these vegetarians, who are
mostly members of the upper economic class, was approxi-
mately one-eighth of the prevelance predicted for that class.
Interestingly, vegetarianism is protective even though, on the-
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Fig. 5. Effects of a short-term increase of dietary animal protein (34 g/24
hours above basal) in 6 normal male subjects on various urinary constit-
uents. 'Probability" score (lower right) refers to a derived index of the risk
of stone formation based on urinary constituents [23].
oretical grounds, increased urinary excretion of oxalate would
be derived from a high vegetable intake [211.
Even more convincing evidence for the role of dietary protein
comes from studies of the response of normal individuals to
dietary protein loading [22—26]. Urinary calcium, oxalate, and
uric acid levels not only increase immediately following inges-
tion of a protein load [23] (see Fig. 5), but this increase persists
for as long as protein intake is high. These urinary changes
increase the probability of nucleation and growth of calcium
oxalate crystals in vitro and of stone formation in vivo [271. Of
course, a high urinary calcium excretion is known to predispose
to stone formation [28].
The mechanism whereby dietary protein leads to hypercalci-
uria, and the reasons for the increased sensitivity of patients
with recurrent nephrolithiasis to the hypercalciuric action of
dietary protein, remain unknown. Dietary protein is hypercali-
uric through a renal effect, either to increase glomerular filtra-
tion rate or to reduce renal tubular calcium reabsorption. There
is no consistent increase in serum ionized calcium level [29].
Lemann and coworkers have shown a clear correlation between
increased renal acid excretion and hypercalciuria [30, 31]. In
experimental animals, acidosis directly inhibits and alkalosis
stimulates calcium transport in the distal nephron [32]. These
findings suggested that the hypercalciuric action of dietary
protein was the consequence of increased endogenous acid
production and thus an increased urinary net acid excretion.
The latter might then inhibit calcium reabsorption in the distal
nephron. Strong evidence against this hypothesis being the
entire explanation for the link between protein loading and
calcium excretion, however, is Lutz' observation that sodium
bicarbonate administration returned urinary pH, ammonium,
and tiratable acid excretion to normal in protein-loaded subjects
but failed to completely correct hypercalciuria [33].
In long-term balance studies in rats, the hypercalciuric action
of dietary protein is quantitatively greatest when methionine is
the principal constituent of the nitrogenous load [34]. This
finding suggests that the sulfate anion, derived from the metab-
olism of the sulfur group contained in methionine, influences
calcium excretion [29]. In addition, the hypercalciuric action of
dietary protein loading correlates well with the urinary excre-
tion of sulfate. It is possible that calcium-sulfate complexes are
formed within the renal tubule, and that these poorly absorb-
able complexes are excreted, thereby producing hypercalciuria.
The lithogenic effects of dietary protein go beyond hypercal-
ciuria to include changes in the excretion of various inhibitors
and promoters of calcium oxalate crystal formation. For exam-
ple, the acidifying effects of a high dietary protein intake could
reduce urinary citrate excretion. Reduced citrate excretion has
been observed in epidemiologic studies of the risk factors for
the formation of recurrent nephrolithiasis [35, 36]. Citrate not
only acts as an important urinary chelator of ionized calcium
[37], but it also is thought to inhibit calcium oxalate crystal
growth [38]. Citrate excretion falls during acidosis as proximal
tubular citrate reabsorption is increased by a more acidic
proximal tubular fluid pH [39]. Moreover, intracellular acidosis
leads to increased citrate utilization in gluconeogenesis and
further favors citrate uptake by proximal tubular cells [39].
A study recently carried out by Dr. Alan Wasserstein at our
Stone Evaluation Center showed that dietary protein restriction
has a citraturic action in hypercalciuric stone formers and that
this alteration is associated with a reduced risk of calcium stone
formation (Wasserstein A, personal communication) (Fig. 6). In
this study of 18 patients with recurrent calcium stone formation,
dietary protein restriction from 96 5 (sEM) to 60—65 glday
significantly raised urinary citrate excretion from 450 44 to
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Fig. 6. Effects of dietary protein and sodium restriction on calcium,
sodium, urate, oxalate, and citrate excretion in Ii hypercalciuric stone
formers. (Permission courtesy of Wasserstein A.)
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Dietary purine intake
mg/kg/24 hr
Fig. 7. Relationship between dietary purine intake and uric acid excretion
in normal subjects. Each point depicts a single measurement of 24-hour
urinary uric acid excretion to average dietary purine intake during the day
of, and the day prior to, the urine collection, with suhjects eating a normal
(0) or a high-meat (9) diet [45].
565 51 mg/day. In a subgroup of hypercalciuric patients (n =
11), reduction of dietary protein from 100 4 to 60-65 g/day
even more markedly elevated citrate excretion (451 49 to 632
58 mg/day) than in the group as a whole. Whether these
hypercalciuric patients also are particularly sensitive to the
hypercitraturic action of dietary protein is unknown.
The ingestion of a high dietary protein intake not only
produces changes in calcium and citrate excretion, but it also
raises urinary uric acid excretion [23]. Coe observed that
increased urinary uric acid is associated with a particularly
severe form of recurrent calcium oxalate nephrolithiasis [401;
several other groups also have studied this phenomenon in an
attempt to unravel the relationship between uric acid excretion
and calcium-oxalate stone formation [41—431.
In-vitro studies had suggested that urate but not uric acid
crystals could act as epitaxial templates and promote calcium
oxalate crystal growth [44], Uric acid crystals are the predom-
inant form in urine, however; urate crystals are rarely found
[44]. Further, urate crystals have a weak ability to promote
crystal growth in highly defined artificial solutions used in
typical in-vitro assays for crystal growth potential [441. Recent
studies have suggested an explanation for these inconsistencies.
Uric acid crystals can adsorb glutamic acid crystals, which in
turn promote calcium oxalate crystal growth [43]. This obser-
vation might explain the potency of uric acid as a promoter of
crystallization in urine but not in artificial solutions because the
former typically contains glutamic acid and other organic
compounds that could increase crystal growth.
ilyperuricosuria in patients with hypercalciuria and renal
stones is typically the consequence of excess dietary purine
consumption, not of an abnormality in purine metabolism [45]
(Fig. 7). Recent carefully controlled studies have shown that
allopurinol is beneficial in reducing the frequency of recurrent
stone formation in patients with calcium oxalate nephrolithiasis
who have hyperuricosuria but who are not hypercalciuric [46].
In Dr. Wasserstein's study, dietary protein restriction did
reduce urinary uric acid excretion. These observations support
the hypothesis that reduction of dietary protein could have an
important therapeutic effect, even in non-hypercaleiuric stone
formers,
In summary, the evidence that a high level of dietary protein
is an important contributing factor to the risk of recurrent
nephrolithiasis derives from (1) population studies showing a
clear correlation between the societal consumption of animal
protein and the prevalence of upper-tract stone disease; (2) the
observation that high dietary protein ingestion raises urinary
calcium, uric acid, and possibly oxalate excretion in normal
individuals; (3) the citraturic and hypocalciuric effect of dietary
protein restriction; (4) the low incidence of nephrolithiasis in
vegetarians and the prophylactic effect of dietary protein reduc-
tion in reducing the risk of stone formation in hypercalciuric
stone-formers; and (5) the beneficial effects of other, pharma-
cologic therapies that reduce urinary uric acid, a typical re-
sponse to dietary protein restriction. What remains to be shown
is that a modification of dietary protein intake will produce a
long-lasting remission from recurrence of stone disease.
Role of dietary sodium
Kleeman et al showed that maneuvers that increase urinary
sodium excretion also increase urinary calcium excretion [47].
This close link prompted an examination of the possible role of
alterations in renal sodium handling as causative in some
instances of hypercalciuria [19]. The only means of producing a
sustained increase in urinary sodium excretion is by ensuring a
sustained increase in sodium intake; therefore dietary sodium
also could be a risk factor for nephrolithiasis.
Calcium and sodium are reabsorbed at various common sites
along the renal tubule [48]. Acute volume expansion produces a
concomitant calciuria as well as a natriuresis. This response
likely involves some inhibition of sodium and calcium reabsorp-
tion in the proximal tubule and along the loop of Henle as well
as inhibition of sodium and calcium transport in the inner
medulla [48]. The calciuric effects of chronic increases in
dietary sodium also are well described, but the intrarenal sites
of altered transport have not been clearly defined. The thick
ascending limb of Henle's loop is one of the likely sites of
reduced calcium transport during high dietary sodium intake;
furosemide and bumetanide administration produce concomi-
tant calciuria and natriuresis by inhibiting calcium and sodium
transport at that site [49].
The old categorization of patients with idiopathic hypercal-
ciuria into those with diet-dependent ("absorptive") hypercal-
ciuria or fasting ("renal") hypercalciuria recently was shown to
be highly dependent on dietary sodium intake [19, 28]. Absorp-
tive hypercalciuria refers to patients who either are hypercal-
ciuric only when the dietary calcium intake is high or to those
who manifest an exaggerated rise in urinary calcium excretion
after oral ingestion of a large calcium load. Renal hypercalciuria
refers to patients who demonstrate a high urinary calcium
excretion (calcium/creatinine, mg/mg, > .12) after an overnight
fast [50]. In fact, fasting hypercalciuria can be attributed to
excess dietary sodium intake in the previous 24 hours in many,
if not the majority of, patients so designated. For example, in
Lau et al's report, patients with renal hypercalciuria ingested
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Fig. 8. Urinary sodium excretion in patients classified as normocalciuric,
absorptive hypercalciuric, or fasting hypercalciuric. Classifications were
based on the fasting urinary calcium excretion (calcium/creatinine ratio
>.12 was considered fasting hypercalciuria) in patients excreting >270mg
calcium/24 hours. The level of urinary sodium excretion (and therefore
sodium intake) was a potential determinant of the classification [51].
approximately 50 mEq/day more sodium than did diet-depen-
dent hypercalciuric patients [51] (Fig. 8). In other studies,
dietary sodium restriction led to a marked and predictable fall in
urinary calcium excretion and prompted the reclassification of
patients with so-called renal hypercalciuria to diet-dependent
hypercalciuria. It has been proposed that specific therapy aimed
at correcting the gastrointestinal hyperabsorption or renal cal-
cium wasting optimizes the care of hypercalciuric patients [52].
However, the dependence of urinary calcium on dietary sodium
intake suggests that such a therapeutic approach is unnecessary
and not based on real pathophysiologic distinctions. Rather, the
vast majority of hypercalciuric patients would respond to a
variety of therapies aimed at either the gastrointestinal tract or
the kidney [28]. Moreover, it appears that hypercaiciuric pa-
tients who undergo a reduction in dietary sodium will typically
have a fall in urinary calcium excretion [19].
In our epidemiologic study, urinary sodium excretion directly
correlated with urinary calcium excretion [171, Moreover, pa-
tients with recurrent calcium stones and hypercalciuria were
more sensitive than were normals to the hypercalciuric action
of dietary sodium, just as they are to dietary protein. Thus,
recurrent stone formers showed a direct relationship between
urinary calcium and urinary sodium excretion but a steeper
slope, suggesting an increased calciuric reponse to all levels of
dietary sodium intake. Similar conclusions were reached by
workers in Australia, who also found that 'atients with recur-
rent calcium stones and hypercalciuria had an exaggerated
calciuric response to dietary sodium; patients with recurrent
renal stones showed a steeper slope for the relationship be-
tween urinary sodium and urinary calcium than did normal
individuals [53].
The relationship between sodium and calcium excretion in
patients with recurrent nephrolithiasis and hypercalciuria was
corroborated by the finding of Sutton and Walker that such
patients had an exaggerated hypercalciuric response to furose-
mide administration [52]. The mechanism of the hyperrespon-
siveness likely is a reduction in calcium reabsorption in the
distal nephron, more distal than the site of action of the
diuretics in the loop of Henle.
Despite these compelling observations, controlled studies
have failed to show that patients with recurrent nephrolithiasis
ingest a greater mean dietary sodium than do controls [161. This
finding suggests that patients with recurrent nephrolithiasis
have an undue sensitivity to calciuric stimuli. Of course, for
those individuals in the population who do consume excess
sodium, the calciuric effect might be even further exaggerated.
For example, in patients reported by Silver and colleagues,
dietary sodium intake of 500—600 mmol/day resulted in massive
hypercalciuria that was abrogated by restriction of dietary
sodium intake [54]. In the study performed by Dr. Wasserstein,
the sodium intake in the patients with hypercalciuria was
reduced from 174 9 to 67 8 mEqfday. This maneuver,
combined with a reduction in dietary protein intake, resulted in
a reduction in urinary calcium from 324 18 to 210 14
mg!day.
Role of dietary oxalate
Hyperoxaluria might be the most important risk factor for
recurrent nephrolithiasis 127]. In principle, urinary oxalate
could be a more important determinant of calcium oxalate
supersaturation than is calcium because small increments in
oxalate excretion markedly raise the activity product of the ions
in the urine [55]. Oxalate is the metabolic end-product of
glycine utilization. The bulk of urinary oxalate is derived from
metabolic pathways, with approximately 40% derived from the
metabolism of dietary ascorbic acid and the remainder from the
conversion of glycolate, glycine, hydroxyproline, and alpha-
hydroxy-beta-ketoadipate [56]. These latter compounds are
found primarily in dietary protein, and increases in dietary
protein potentially could raise urinary oxalate excretion. Under
normal circumstances, the pathways for the metabolism of
ascorbate to oxalate are saturated, and thus an increase in
dietary intake does not necessarily result in a rise in urinary
oxalate excretion [57]. In some susceptible individuals, howev-
er, urinary oxalate excretion increases markedly following the
ingestion of ito 2 g of ascorbate [58]. Vitamin B6, as pyridoxal
phosphate, also plays a key role in oxalate metabolism, being a
cofactor in the interconversion of glycine and glyoxalate. A
deficiency of this vitamin results in increased formation and
excretion of oxalate [55].
Oxalate itself is a common component of food, but the
content is typically low (<0.01 mmol/lOO g) [59]; some foods
have a high oxalate content, and ingestion of these foods can
lead to hyperoxaluria. The urinary oxalate level is higher in
patients with recurrent nephrolithiasis [60]. Three explanations
might account for sustained hyperoxaluria in patients with
recurrent nephrolithiasis: these patients might ingest excess
oxalate. absorb a higher fraction of a normal dietary intake, or
have a metabolic defect leading to increased oxalate synthesis.
Excess dietary oxalate content occasionally is found in
patients with nephrolithiasis, particularly in those who consume
foods such as spinach, rhubarb, peanuts, strawberries, choco-
late, and tea [551, but epidemiologic studies have revealed no
consistent increase; evidence for hyperabsorption of oxalate
per se has been offered [601 but has not been confirmed [61]. An
important relationship exists between gastrointestinal oxalate
and calcium absorption: the presence of unabsorbed, unbound
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calcium in the intestinal lumen can complex with oxalate ions
and prevent oxalate (and calcium) absorption. Conversely, with
a reduction in calcium in the intestinal lumen, oxalate absorp-
tion and excretion increase. This mechanism has been proposed
to explain the hyperoxaluria commonly seen with gastrointes-
tinal malabsorption [55]. In this setting, calcium complexes with
unabsorbed dietary fat, leading to hyperoxaluria by rendering
dietary oxalate more easily absorbed. Alternatively, alterations
in colonic permeability to oxalate (perhaps induced by unab-
sorbed bile salts) have been proposed to explain the intestinal
hyperabsorption of oxalate in patients with intestinal hyperox-
aluria [62].
Because gastrointestinal calcium hyperabsorption occurs in
patients with idiopathic hypercalciuria, Tiselius proposed that
less calcium is delivered to more distal portions of the small
intestine; thus abnormally large fractions of ingested oxalate are
absorbed [63]. Whether or not this is the case, patients with
recurrent nephrolithiasis—particularly those with hypercalci-
uria—tend to excrete a larger fraction of ingested oxalate [64].
Massive hyperoxaluria can occur in a variety of genetic
disorders of oxalate metabolism, but no evidence has been
adduced that a primary defect in oxalate metabolism occurs in
the usual patient with recurrent nephrolithiasis.
The utility of reducing dietary oxalate intake to lower urinary
oxalate excretion in patients with calcium oxalate stones has
been questioned [55]. Several studies have shown, however,
that in patients with recurrent nephrolithiasis, and even in those
with primary hyperoxaluria, reducing dietary oxalate intake
does lower renal oxalate excretion [65]. This maneuver is
particularly effective in patients ingesting a diet high in oxalate.
Moreover, patients with nephrolithiasis treated by dietary oxal-
ate restriction maintain a sustained reduction in urinary oxalate
excretion if they are able to comply with the diet [66]. The
importance of dietary modification in patients with calcium
oxalate nephrolithiasis is emphasized by the fact that no phar-
macologic therapy has been consistently successful in reducing
urinary oxalate excretion. Pyridoxine administration has been
proposed, but it is not uniformly effective in reducing urinary
oxalate excretion [551.
Role of dietary calcium
There is little dispute that increased gastrointestinal calcium
absorption occurs in patients with hypercalciuric nephrolithia-
sis [67], although it is still unknown whether excess gastroin-
testinal calcium absorption is a primary event. The mechanism
of the hypercalciuria also remains unknown, although elevated
1 ,25(OH)2 vitamin D levels likely contribute to elevated calcium
absorption in the gut 168].
Dietary calcium restriction has been a mainstay of therapy for
the prevention of recurrent nephrolithiasis. Recent studies have
suggested that this is an inappropriate and even potentially
detrimental form of therapy, however. First, in experimental
studies of normal individuals and of patients with recurrent
nephrolithiasis and hypercalciuria, severe dietary calcium re-
striction (<400 mg/day) resulted in a markedly negative calcium
balance in most patients [69]; urinary calcium fell slightly but
gastrointestinal calcium losses persisted. This negative calcium
balance can be attributed to the elevated 1 ,25(OH)2 vitamin D3
levels typically found in patients with idiopathic hypercalciuria.
Administration of l,25(OH)2 vitamin D3 to normal volunteers
on a low calcium intake produces a negative calcium balance, as
bone resorption is stimulated and calciuria persists despite the
low intake 170].
Negative calcium balance can be exaggerated in patients
ingesting a low-calcium diet with a particularly high dietary
protein intake [71]. The loss of bone calcium, if large enough,
eventually could produce osteoporotic bone disease, particu-
larly in older, female patients. In fact, osteopenia has been
found in some groups of hypercalciuric patients with recurrent
nephrolithiasis [72]. Studies of the hypercalciuric action of
dietary protein loading demonstrate that the concomitant inges-
tion of a low-calcium, high-protein diet is particularly likely to
lead to a negative calcium balance, even in otherwise healthy
individuals [73].
Second, the severe restriction of dietary calcium can produce
hyperoxaluria by stimulating gastrointestinal oxalate absorp-
tion. This partially explains the poor response to so-called
"general advice," typically including dietary calcium restric-
tion, that has been reported in the literature [74, 75].
Finally, studies by Lemann et al suggest that the relationship
of urinary calcium excretion to dietary calcium intake is such
that only 6% of an oral calcium load appears in the urine in
normal individuals [31]. In fact, the high urinary calcium levels
found in population studies of countries with a high incidence of
upper-tract stone disease likely is due to the relatively high
protein intake in these countries, rather than to an excess of
dietary calcium [15].
I thus conclude that dietary calcium restriction is unlikely to
produce a beneficial action in reducing the frequency of new
stone formation in patients with recurrent nephrolithiasis. In
fact, a detrimental effect may result, as negative calcium
balance and secondary hyperoxaluria are potential outcomes of
severe dietary calcium restriction.
Role of fluid intake
Recurrent nephrolithiasis occurs in individuals from temper-
ate climates who reside for long periods in tropical climates.
British naval personnel stationed in the Middle or Far East, for
example, have a higher incidence of stones than do their
counterparts stationed in Great Britain [76]. In Israel, the risk of
renal stone formation is substantially greater in individuals
residing in villages in the hot, dry desert areas compared with
those living in more temperate areas [77] (Fig. 9). The role of
fluid intake inadequate to maintain normal hydration and rela-
tively dilute urine has been implicated in this phenomenon. In
patients under treatment for recurrent calcium stones, a urinary
volume less than 1400 ml/day conveys an increased risk of
recurrence of stone formation 178]. Also, the prescription of a
high fluid intake is one of the components of the effective,
conservative management program suggested by Hosking et al
as explaining the "stone clinic effect" [5], in which the mere
entry into a specialized stone treatment program reduces the
frequency of stone formation from 0.7 to 0.1 episodes/patient/
year.
Fluid therapy is theoretically harmful: if inhibitors of calcium
oxalate crystal growth are an important urinary defense mech-
anism against stone formation, then diluting these inhibitors
with a high urine flow paradoxically could increase the risk of
stone formation. Studies of the formation-product ratio and the
activity-product ratio of urine diluted in vitro or in vivo fail to
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ment are considered the "diet control" group hardly represent
valid, therapeutic trials for non-pharmacologic treatment [81].
Another important criticism of most clinical trials on the
prevention of recurrent nephrolithiasis is that these studies
typically employ the period immediately preceding treatment as
the baseline period to determine the frequency of stone forma-
6 tion and compare this brief baseline period with the 2- to 3-year
interval after treatment begins. The frequency of stone forma-
tion likely falls towards a mean value (regression to the mean),
so it is inappropriate to perform such pre- to post-therapyt comparisons [81].
Finally, as Churchill points out, a number of other important
criteria are rarely satisfied in clinical trials of various pharma-
cologic agents [81]; these criteria include the use of randomized
g populations, appropriate statistical and clinical outcomes, corn-
2 plete followups, and full accounting of dropouts. Churchill
concluded that only two trials with thiazides [46, 84] and one
with allopurinol [871 are scientifically valid [81]. The thiazide
trials included less than 30 patients in each; thus the most
commonly used agent for the prevention of recurrent nephroli-
0 thiasis hardly has been subjected to adequate testing. I am not
arguing that thiazide administration is not an effective and safe
method for achieving a normal urinary calcium excretion; I say
only that such therapy has not been proved to be the best choice
available. I already noted the possibility of untoward long-term
effects of thiazide diuretics [4]. Moreover, the clear epidemio-
logic and experimental data showing the important pathophys-
iologic role of diet in the pathogenesis of recurrent nephrolithi-
asis support the hypothesis that modifications in diet and fluid
intake ought to be attempted first in appropriately selected
patients.
My profile for the patient most likely to benefit from dietary
manipulation is as follows: First, individuals whose dietary
sodium, protein, oxalate, and (rarely) calcium are excessive or
whose urinary volume is unusually low should undergo specific
attempts to have their diets modified. Obviously, the level that
defines "excessive" cannot be precisely defined. Consuming no
more than 100 mEq/day sodium, 1 g/kg protein, and 1000—1500
mg calcium, and avoiding oxalate-rich foods and ingesting at
least 2000 ml124 hours of fluid is prudent and without risk. A
high dietary fiber intake also can be beneficial in lowering
dietary calcium and oxalate absorption, although the impact of
the high fiber on overall external calcium balance has not been
fully assessed. All patients should be advised to pursue the
recommended diet, particularly while the "metabolic activity"
of their stone disease is being determined. If careful dietary
history and measurement of sodium intake (as assessed by
24-hour urinary sodium excretion), protein intake (as assessed
by the 24-hour urinary urea nitrogen excretion), and fluid intake
(as assessed by 24-hour urinary volume) document important
deviations from the recommended values for the intake of these
dietary components, dietary modification is a highly rational
approach.
Patients should not receive specific pharmacologic treatment
if stone activity is not documented, that is, if stone growth or
new stone formation does not occur while the patient is under
medical observation; the passage of a previously formed stone
is not sufficient evidence to warrant specific pharmacologic
intervention.
Studies have assessed whether patients adhere to dietary
t
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Fig. 9. Relative probability offorming a kidney stone based on the relative
constituents of the urine [15] is plotted in relation to 24-hour urinary
volume in normals (0). The prevalence of stones in three populations in
Israel compared with the average fluid intake in the three villages studied
is also shown (•) [77].
demonstrate increased risk for stone formation with increasing
urinary dilution, however [79].
Perhaps the most important spur to patient compliance with
fluid therapy is a specific prescription of the amount and
frequency of water intake [80]. Also, the fluid intake must not
contain carbohydrates or oxalate, such as fruit juices, or the
beneficial effects of the fluid will be negated by the increased
excretion of the lithogenic components [181.
Evidence for the efficacy of dietary therapy in the prevention
of recurrent nephrolithiasis
The most important question that emerges from this discus-
sion is whether dietary manipulation prevents recurrent neph-
rolithiasis. Before considering this issue, it is appropriate that
we question whether any effective pharmacologic therapies that
have undergone rigorous clinical trials are available. Churchill
and colleagues have proposed requirements for defining an
adequate clinical trial and have analyzed the published trials of
various pharmacologic interventions [3, 8k]. Many of these
criteria are appropriate for any clinical trial, but several are
particularly relevant to nephrolithiasis. For example, most
trials of nephrolithiasis have not employed a control group; the
importance of concomitant interventions, such as dietary ma-
nipulation and increased fluid intake, was not assessed. This
deficiency could explain the "stone clinic effect" alluded to
earlier. Similar impressive responses have been achieved with
dietary advice in other studies [82, 83]. The magnitude of this
benefit mimics that attributed to thiazide treatment in many
studies [81]. Studies that claim failure for diet therapy but in
which patients who do not comply with pharmacologic treat-
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intervention. Some studies have shown a poor result, with less
than 40% of patients compliant after 6 months [75]. Other
studies have achieved far better results, perhaps because of the
physician's enthusiasm for such therapy [80]. It appears that
reduction of urinary oxalate and calcium as well as increased
urinary volume all can be maintained for at least 3 months [60]
and, in many patients, probably for at least 6 years [5].
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Dr. Goldfarb,
you discussed the decrease in urinary calcium excretion that
occurs when dietary sodium intake decreases. Let's look at this
in reverse. If you increase dietary sodium intake from 100 to 300
mEq/day and thus increase urinary calcium excretion, where
does that calcium come from? Does it come from bone? If so,
can the bone calcium loss actually result in metabolic bone
disease?
DR. GOLDFARB: The rise in urinary calcium after an increase
in dietary sodium is due to increased dietary calcium absorption
and possibly to increased bone resorption. Breslau et al showed
that in normal individuals, increasing sodium intake from 10 to
240 mEq/day led to a 57 mg/day increase in urinary calcium
excretion and increases in serum iPTH, l,25(OH)2D, and frac-
tional intestinal 47calcium absorption [85]. In patients with
hypoparathyroidism, urinary calcium increased as in normals,
but the response in l,25(OH)2D, in iPTH, and in fractional
intestinal 47calcium absorption all were abolished. These data
suggest that in normal individuals, the increase in calcium
excretion secondary to increased sodium excretion results in a
slight fall in serum calcium and a compensatory increase in PTH
release. This, in turn, stimulates renal production of 1 ,25(OH)2D,
and ultimately results in a rise in intestinal calcium absorption.
In theory, elderly individuals who have an impaired capacity to
synthesize 1 ,25(OH)2D [861 could develop a markedly negative
calcium balance when consuming large amounts of sodium and
thereby have an increased risk of bone disease, but we have no
data yet to assess this possibility.
The evidence is clearer that the ingestion of a low-calcium,
high-protein diet in older individuals results in negative calcium
balance and, therefore, in an increased risk of bone calcium
depletion and osteoporosis [29].
DR. NIc0LA0s E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): You
alluded to the sensitivity of recurrent calcium stone formers to
the calciuric effect of dietary protein. Is there a similar effect for
purine intake? Are hyperuricosuric patients with recurrent
nephrolithiasis more sensitive to the uricosuric effect of dietary
purine as compared with appropriate controls?
DR. GOLDFARB: As I noted, the uric acid excretion after a
purine load is not greater in stone formers than in normal
individuals [45]. The cause of hyperuricosuria in hypercalciuric
patients is increased purine intake. Hypersensitivity to the
hypercalciuric effects of dietary carbohydrate intake has been
observed not only in stone formers but also in their close
relatives [18]. The mechanism of this latter phenomenon might
be an exaggerated response of insulin secretion to ingested
carbohydrate in stone formers [87]; evidence exists for a direct
hypercalciuric action of insulin on the kidney [88].
DR. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): You've shown that increased dietary
protein increases urinary calcium excretion. Have these studies
been carefully evaluated as to dietary phosphorus and urinary
phosphorus excretion? Are we sure that it is protein and not
phosphorus that alters urinary calcium excretion?
DR. GOLDFARB: A high dietary phosphate level actually
decreases urinary calcium excretion [89]. This effect is complex
and involves both direct stimulation of distal nephron calcium
reabsorption [901 and decreased bone resorption [91]. Thus,
whereas sulfate may complex calcium to promote urinary
calcium excretion, phosphate has an entirely dissimilar effect.
There is no evidence that any of the renal actions of phosphate
ion are mediated by complexation of extracellular ionized
calcium. Furthermore, hypophosphatemia is commonly present
in patients with hypercalciuria [921. This observation raises the
possibility that a mild degree of phosphate depletion produced
by a primary disorder in renal tubular phosphate transport
underlies idiopathic hypercalciuria in patients [51].
In metabolic balance studies aimed at defining the interaction
among calcium, protein, and phosphate intake, the addition of
phosphorus to the diet had a beneficial effect: it moderated the
rise in urinary calcium as dietary protein intake was increased
[93]. It alone will not abrogate the rise in urinary calcium
induced by high dietary protein intake, however.
DR. HARRINGTON: You mentioned the importance of inhibi-
tors of urinary calcium precipitation. Do the alterations in diet
that you have been discussing have any direct effect on the
concentration of these inhibitors in the urine?
DR. GOLDFARB: We do not have a great deal of information
on this point. A high dietary phosphate level could increase the
urinary excretion of pyrophosphate, an important inhibitor of
calcium-phosphate crystal formation. Clearly, dietary protein
has an important influence on citrate excretion. An acidic
glycoprotein (molecular weight approximately 14,000 daltons)
recently was described that is the major inhibitor of calcium
oxalate crystal growth in vitro [94]. This protein is altered in
patients with recurrent calcium oxalate stone formation [95];
the influence of various dietary constituents on the excretion of
this inhibitor has not yet been studied.
DR. MADIAS: To what extent is the beneficial effect of
administered citrate on recurrent stone formation due to its
alkalizing effect? Are there studies comparing the effect of
citrate to that of an equivalent amount of bicarbonate?
DR. GOLDFARB: Any alkalizing agent will increase urinary
citrate excretion, but the comparative efficacy of various alka-
line salts has not been evaluated. Citrate has the advantage that
it produces little of the gastrointestinal discomfort that usually
accompanies the ingestion of large oral doses of sodium bicar-
bonate, and it does not obligate a large sodium load, which
could induce an increase in calcium excretion.
DR. BHARAT V. SHAH (Clinical Research Fellow, Division of
Nephrology, New England Medical Center): What percentage
of your patients complied with the low-protein, low-sodium,
and every-two-hour water intake regimen? Among those who
complied, what percentage did not have stone recurrence?
DR. GOLDFARB: Dr. Wasserstein's study did not test compli-
ance, so I cannot answer your question. Patients with recurrent
stone disease generally comply with dietary recommendations,
but compliance varies from institution to institution. The enthu-
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siasm of the prescribing physician for a given therapy is an
important variable in its acceptance by the patient [801. Patients
who self-select low fluid intakes frequently are quite surprised
at their low 24-hour urine volume and are willing to increase
their fluid intake as prescribed.
The patients most likely to benefit from a dietary approach to
prophylaxis are those whose intake of protein or sodium is
unusually large. I do not advocate a very low sodium or protein
intake, but I do recommend that patients modify their diets as I
outlined. If diet and fluid therapy are as important as suggested
by epidemiologic data, this approach could eliminate 40% to
50% of stone recurrences. Patient compliance and the long-term
benefit of these specific dietary interventions is yet to be
determined.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): How extensively do you eval-
uate a patient with hypercalciuria for its underlying cause?
DR. GOLDFARB: Patients must be screened to rule out forms
of secondary hypercalciuria, that is, increased urinary calcium
excretion due to hypercalcemia or to recognized abnormalities
such as sarcoidosis, or massive milk or vitamin D intake. This
requires taking a careful history and obtaining at least two
determinations of the serum calcium level. We also evaluate
patients on their self-selected diets and monitor their protein
and sodium intakes by measuring urinary urea nitrogen and
sodium. Individuals who have hypercalciuria and evidence of
high protein or sodium intake are given a diet restricted in
protein (<0.8 mg/kg) and sodium (<100 mEq/day) and renal
calcium excretion is reassessed to determine the patient's
response. We do not evaluate gastrointestinal calcium absorp-
tion or the level of fasting hypercalciuria because of the lack of
specificity of this approach, as I previously noted [28]. It is
likely that any reduction of urinary calcium is beneficial in
patients with recurrent calcium nephrolithiasis and that any
increase in urinary volume also will benefit all patients. We
therefore recommend a high fluid intake as well.
DR. HARRINGTON: Given this body of new information on the
effect of manipulation of dietary constituents on urinary cal-
cium excretion, what do you consider the present role of
thiazide diuretics or cellulose phosphate?
DR. GOLDFARB: I believe that thiazide diuretics are an
effective treatment for hypercalciuria and probably decrease
the risk of renal stone recurrence. This view is largely anecdot-
al, however, and has only been substantiated in two small
clinical trials [81]. The long-term risk of thiazides remains
unknown and is a point of some controversy in the therapy of
mild hypertension. The ability of thiazide diuretics to reduce
urinary calcium excretion is salutary, and I am unaware of any
evidence that thiazide diuretics have any detrimental actions on
calcium metabolism, such as causing soft-tissue calcifications
due to positive total-body calcium balance.
Cellulose phosphate is rarely used because it is so effective in
reducing intestinal calcium absorption that increased oxalate
excretion is a frequent side effect [961. No studies have shown
that cellulose phosphate is really better than are diet and high
fluid approaches, and it has not been tested in any acceptable
controlled trials.
Da. MADIAs: Would you comment on the effect of alcohol
intake on stone formation?
DR. GOLDFARB: There is evidence from a study conducted in
Austria that increasing alcohol consumption is nearly linearly
correlated with increasing urinary calcium and uric acid excre-
tion [97]. Whether this effect on urinary composition translates
into an increased risk of stone formation has not been assessed.
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